Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

657 - Ovarian granulosa cell tumours: hormone receptor positivity and response to aromatase inhibitors


08 Oct 2016


Poster Display


Kathryn Herring


Annals of Oncology (2016) 27 (6): 296-312. 10.1093/annonc/mdw374


K. Herring1, R. Ganesan2, A. Rao1, L. Edwards2, J. Pascoe1, S. Williams1

Author affiliations

  • 1 Medical Oncology, University Hospitals NHS Trust, B15 2GW - Birmingham/GB
  • 2 Histopathology, Birmingham Womens Hospitals NHS Trust, B15 2GW - Birmingham/GB


Abstract 657


Ovarian granulosa cell tumours (GCT) are rare gynaecological malignancies with recurrence possible decades after initial treatment. Although mostly treated surgically, often chemotherapy and aromatase inhibitors (AIs) are used with little supporting data. Despite evidence in breast and epithelial ovarian cancer that hormone receptor expression predicts response to AIs, there is no such evidence in GCTs. Oestrogen/progesterone receptor (ER/PR) status poorly reported in case series. Study aim: evaluate clinical efficacy of hormonal manipulation in GCT, correlation of efficacy with immunohistochemical (IHC) marker presence.


Clinical details, demographics, survival data collected- 15 patients with recurrent GCT treated 2004-2014 in large UK centre. ER/PR IHC performed on tumour samples available. Primary outcome: progression free survival on hormonal manipulation (PFS). Secondary outcomes: ER/PR positivity, correlation with response to treatment.


Median age at diagnosis 54 years (range 29-78years). Median interval from diagnosis to detection of recurrence/advanced disease 5 years (range 0.3-21years). Ten patients (67%) received hormonal manipulation, often previously heavily pretreated. Chemotherapy trialed in 4 patients, multiple lines given prior to commencing hormonal manipulation. AI/GnRH prescribed on 14 occasions, sometimes multiple lines in the same patient. Median PFS 14 months (95%CI 11.04-16.95), 5 patients continue to respond at time of analysis. Tumour analysed in 9 instances of hormonal manipulation. ER+ related to longer PFS in those treated with AIs, median 20.5 months (range 9-32); 14 months (range 3-24) in ER- cases.

ER/PR status and progression free survival in episodes of management with hormonal manipulation

Hormonal agent Line of treatment post recurrence ER/PR (Q score) Time to radiological progression from commencement of hormonal agent (months)
GnRH 2nd 5/8 3^
2nd 0/8 4
Letrozole 1st 0/5 15
3rd 0/8 3
4th 6/7 32^*
4th 4/8 9
4th 5/8 32*
4th 0/8 24
5th 2/6 13

^= same patient

*= censored data, continues to respond


PFS comparable to previous reviews with particularly good response from letrozole. ER+ potentially correlates with prolonged response with AIs,but also seen in ER-. Prospective studies would further clarify usefulness of AIs as standard of care and utility of ER IHC to predict response.

Clinical trial identification

Not applicable.

Legal entity responsible for the study



Charitable funding donated to Dr Sarah Williams


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings